Boussiotis, Vassiliki A.

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 2,955

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 606

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation

Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 529

Targeted deletion of PD-1 in myeloid cells induces antitumor immunity

Strauss, L., Mahmoud, M. A. A., Weaver, J. D., Tijaro-Ovalle, N. M., Christofides, A., Wang, Q., Pal, R., Yuan, M., Asara, J., Patsoukis, N., et al. (2020) · Science Immunology

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 437

CTLA-4 regulates induction of anergy in vivo

Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K., & Sharpe, A. H. (2001) · Immunity

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 428

Interaction of SHP‐2 SH2 domains with PD‐1 ITSM induces PD‐1 dimerization and SHP‐2 activation

Patsoukis, N., Duke-Cohan, J. S., Chaudhri, A., Aksoylar, H.-I., Wang, Q., Council, A., Berg, A., Freeman, G. J., & Boussiotis, V. A. (2020) · Communications Biology

Protein Tyrosine PhosphatasesT-cell and B-cell Immunology

Cited by 169

The PD‐1 Interactome

Wang, Q., Bardhan, K., Boussiotis, V. A., & Patsoukis, N. (2021) · Advanced Biology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 39